Systemic Antifungal Agents.
- Author:
Jun Hee WOO
1
;
Doo Ryeon CHUNG
;
Jiso RYU
Author Information
1. Department of Internal Medicine, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Systemic antifungal agents
- MeSH:
Amphotericin B;
Antifungal Agents*;
Candida;
Danazol;
Echinocandins;
Fluconazole;
Fusarium;
Humans;
Itraconazole;
Ketoconazole;
Transplants;
Trichosporon
- From:Korean Journal of Medical Mycology
1997;2(2):110-122
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
There is an increasing tendency of systemic fungal infection because of increase in the number of immunocomproised patients such as the patients receiving anticancer chmotherapy or organ transplant. The frequency of systemic fungal infection is problematic, since it is often difficult for clinicians to manage the patients with fungal infection. Amphotericin B was one of the representativ antifungal agent for the systemic antifungal infection even though it has many kinds of advers reactions for instance nephrotoxicity, electrolyte imbalance, etc. Therefore ketoconazole, fluconazole, and itraconazole were develped and prescribed with effect. Because of increase in the number of resistant strains of Candida, Fusarium or Trichosporon nowadays, as for azole antifungal agents there were something to be desired. Other new antifungal agents with fungicidal effect under develpment include polyoxins, echinocandins and pradimicin.
